"Ethambutol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
| Descriptor ID |
D004977
|
| MeSH Number(s) |
D02.092.782.258.368.265
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ethambutol".
Below are MeSH descriptors whose meaning is more specific than "Ethambutol".
This graph shows the total number of publications written about "Ethambutol" by people in this website by year, and whether "Ethambutol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ethambutol" by people in Profiles.
-
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938.
-
Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, Barnes GL, Hoffman J, Chaisson RE, McIlleron H, Dorman SE. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015 Jul; 19(7):780-6.
-
Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, Namaganda C, Mboowa G, Nakayita G, Armakovitch S, Chien G, Cho SN, Via LE, Barry CE, Ellner JJ, Alland D, Dorman SE, Joloba ML. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother. 2014; 58(1):11-8.
-
Naidu VG, Tammineni AK, Biscopink RJ, Davis TL, Veerabagu MP. Coccidioides immitis and Mycobacterium tuberculosis diagnosed by endoscopic ultrasound. J S C Med Assoc. 2009 Feb; 105(1):4-7.
-
Szklo A, Mello FC, Guerra RL, Dorman SE, Muzy-de-Souza GR, Conde MB. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. Int J Tuberc Lung Dis. 2007 Jul; 11(7):775-80.
-
Grujic M, Praso R, Milovanovic M, Budisavljevic M, Djuric O, Laban M, Macanovic J, Malenic S, Martinis U, Nikolic A, Popovic J, Putnik D, Stosic A, Vanic D, Zegarac D. [First experiences in the treatment of pulmonary tuberculosis with myambutol at the Institute for Tuberculosis of the SR Serbia]. Plucne Bolesti Tuberk. 1969 Apr-Jun; 21(2):212-7.